Form D · Biotechnology

Esculon, Inc.

Omaha, NE · CIK 0001709643

Offering snapshot reported Nov 27, 2017 · SEC filing

Reported sold
$2.93M
Offering amount: $2.93M
Investors reported
14
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 7, 2017
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.46M$2.93MJun 19, 2017: $969,680.00Jun 19, 2017Jun 19, 2017: $1,554,984.00Nov 27, 2017: $2,925,826.00Nov 27, 2017

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$969,680 → $2,925,826

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 27, 2017Amendment$2,925,826$1,956,146vs Jun 19, 201714SEC filing
Jun 19, 2017Initial$969,680No comparison14SEC filing
Jun 19, 2017Amendment$1,554,984$585,304vs Jun 19, 201714SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-288997
Amendment is to increase total offering amount. Also updated amount sold as of date of amendment.

Source: Form D, filed Nov 27, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Danial Burnett Director
Alan Chesler Director
Deepak Gangahar Director
Evan Luxon Director
Carter Meyer Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3929 Harney Street Suite 3008
Omaha, NE, 68198